FUCOIDAN RESEARCH UPDATE
Fucoidan Human Research: A Look at Recent Clinical Findings on Undaria pinnatifida
What a new randomized, placebo-controlled study found — and what it doesn't (yet) tell us.
Research Roundup · July 2026
Fucoidan is a natural polysaccharide found in brown seaweeds such as Undaria pinnatifida (also known as wakame), Mozuku, and Fucus. It has been the subject of ongoing scientific research exploring its properties, including antioxidant activity and its role in supporting the body's natural processes. As part of our commitment to staying informed on the latest fucoidan research, we wanted to share a recently published study that we found particularly interesting.
In July 2026, a study titled “Fucoidan from Undaria pinnatifida Improves Benign Prostatic Hyperplasia Symptoms in Men: A Randomized, Double-Blind, Placebo-Controlled Study” was published in the peer-reviewed journal Research and Reports in Urology. The study was funded by a supplier of Undaria pinnatifida fucoidan extract.
|
95
Men, ages 45–80
|
90
Days duration
|
RCT
Double-blind, placebo-controlled
|
The 90-day study involved 95 men aged 45–80 with moderate benign prostatic hyperplasia (BPH), a common and non-cancerous prostate condition that becomes more prevalent with age. Participants were randomly assigned to receive either a daily fucoidan supplement or a placebo, and neither participants nor researchers knew who received which (a “double-blind” design, considered a gold standard in clinical research).
What the Researchers Reported
According to the published results, participants in the fucoidan group showed statistically significant improvements in their International Prostate Symptom Score (IPSS) — a standard questionnaire used by clinicians to assess urinary symptoms — compared to those who received the placebo. The researchers also reported improvements in quality-of-life measures related to urinary symptoms, and noted that fucoidan was well tolerated, with prostate-specific antigen (PSA) levels remaining within normal ranges throughout the study.
Limitations Noted by the Researchers
● The sample size was relatively small (95 participants) and conducted at a single point in time.
● The 90-day duration limits what can be concluded about longer-term effects.
● Several secondary measurements (such as urinary flow rate) did not show statistically significant differences between groups.
● The researchers called for larger, longer-term studies to confirm these findings.
“The magnitude of improvement observed in the present study should be interpreted within the context of a nutraceutical intervention and not as equivalent to established pharmacological therapies.”
We think it's valuable to stay informed about emerging fucoidan research, and this study represents a rigorously designed clinical trial on a topic — prostate health — that affects many men as they age. That said, this is one study on a specific type of BPH population, and science generally requires multiple independent studies over time before firm conclusions can be drawn.
This article is for informational purposes only. If you have questions about BPH or any prostate-related symptoms, please consult a qualified healthcare provider, who can evaluate your individual situation and discuss appropriate options with you.
This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
This article discusses third-party published research and does not constitute a claim about any Nature Medic product.
